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Brief Clinical ReportsTricuspid valve replacement and ventricular septal defect repair in
a patient with Glanzmann thrombastheniaJake Gillen, BS,a John Lazarchick, MD,b and Fred A. Crawford, Jr, MD,c Charleston, SCWe describe the successful replacement of an incompe-
tent tricuspid valve and repair of a ventricular septal defect
(VSD) in a patient with Glanzmann thrombasthenia, a con-
genital defect of platelet aggregation.CLINICAL SUMMARY
A 30-year-old woman had symptoms of right-sided heart
failure. She had a VSD known since birth and a history of
tricuspid valve endocarditis at the age of 17 years, resulting
in severe tricuspid insufficiency. During the previous 6 to
12 months, she had noted increasing dyspnea with exertion.
Physical examination revealed a 3/6 holosystolic murmur
throughout the precordium. Echocardiography revealed a re-
strictive membranous VSD with 2:1 left-to-right shunt, se-
vere tricuspid regurgitation, and severe right ventricular
and right atrial enlargement. Left ventricular ejection frac-
tion was 60%.
The patient was known to have Glanzmann thrombasthe-
nia, a disorder of platelet aggregation. Despite this diagno-
sis, she had minimal problems with bleeding, with only
a single hospitalization for severe epistaxis at the age of
22 years and occasional epistaxis and gingival bleeding
since then. She had undergone an ovarian cystectomy at
the age of 28 years and received blood and platelet transfu-
sions perioperatively.
Preoperative hematologic workup confirmed the diagno-
sis and the absence of circulating antiplatelet antibodies de-
spite previous platelet transfusion. The decision was made to
proceed with surgery with adequate quantities of platelets
available for transfusion.
The patient received 2 units of platelets just before surgery,
and standard cardioprotective techniques were used, includ-
ing heparin anticoagulation and cardiopulmonary bypass
with antegrade cold blood potassium cardioplegia. The 10-
mm VSD was repaired with a patch. The destroyed tricuspid
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lif). Total cardiopulmonary bypass time was 107 minutes,
with an 82-minute crossclamp time. Postoperative echocar-
diography revealed no intracardiac shunt and a well-seated
tricuspid valve without paravalvular leakage. Intraoperative
bleeding was not different from that in a patient with normal
platelet aggregation. Postoperatively chest tube drainagewas
470mL.The patient received an additional 2 units of platelets
on postoperative day 3. Recovery was uncomplicated, and
she was discharged on postoperative day 8.
DISCUSSION
Glanzmann thrombasthenia is characterized molecularly
by a defect in the glycoprotein IIb/IIIa complex on the surface
of platelets. This complex binds fibrinogen and other clotting
factors and is involved in platelet aggregation. Patients with
this disease have normal platelet counts but abnormal platelet
function. Their platelets aggregate appropriately in response
to ristocetin but not adenosine diphosphate, collagen, epi-
nephrine, or thrombin. This disorder is inherited in an autoso-
mal recessive manner, with increased incidence seen with
consanguineous parents. These patients commonly have ep-
istaxis, gingival bleeding, purpura, and menorrhagia. They
exhibit easy bruising and prolonged physiologic bleeding,
but visceral hemorrhages, hemarthrosis, and spontaneous un-
provoked bleeding events are rare. For most patients, the dis-
ease has minimal effects on their normal daily lives.1
Management of these patients consists primarily of plate-
let transfusions, either prophylactically before procedures in
which bleeding is expected or to help stop an acute bleeding
event. Some patients have antiplatelet antibodies develop af-
ter repeated transfusions, and their condition becomes refrac-
tory to treatment with further transfusions. Recombinant
factor VIIa and antifibrinolytic agents have been used with
some success in such cases.2 Hematopoietic stem cell trans-
plant has also been used for patients with recurrent severe
bleeding or resistance to platelet transfusions.3
Although there have been numerous reports of patients
with Glanzmann thrombasthenia undergoing abdominal,
pelvic, orthopedic, and dental surgery, there have only
been 2 other reports to our knowledge of affected patients
who have undergone cardiac surgery. A 77-year-old woman
underwent coronary artery bypass grafting, complicated by
cardiac tamponade on postoperative day 2. She was found
to be HLA sensitized postoperatively, explaining her
marked consumptive thrombocytopenia.4 An 8-year-old
boy with Glanzmann thrombasthenia underwent VSDgery c May 2010
Brief Clinical Reportsrepair. Before the operation, he received 6 units of platelets
and intravenous desmopressin at 0.3 mg/kg every 2 hours for
4 doses. He was discharged on postoperative day 8 without
complications.5
Our patient underwent a careful preoperative hematologic
workup to rule out antiplatelet antibodies and to match donor
platelets for compatibility. She received 2 units of platelets
just before the operation and was then monitored carefully
for clinical and laboratory signs of coagulopathy. Extra at-
tention was also paid to precise surgical technique. The Ver-
ifyNow IIb/IIIa assay (Accumetrics, Inc, San Diego, Calif),
typically used to assess levels of functioning platelets in pa-
tients treated with glycoprotein IIb/IIIa inhibitors such as ab-
ciximab or eptifibatide, was used perioperatively to monitor
levels of properly functioning platelets.6
We conclude that patients with Glanzmann thrombasthe-
nia are able to undergo heart surgery despite their bleeding
diathesis, as long as care is taken in proper preoperativeFrom the Divisions of Trauma and Critical Carea and Thoracic and Cardiovascular
Surgery,b Broward General Medical Center; and the Division of Oral Maxillofacial
Surgery,c NOVA Southeastern University, Fort Lauderdale, Fla.
Disclosures: None.
Received for publication Jan 23, 2009; revisions received Feb 12, 2009; accepted for
publication Feb 24, 2009; available ahead of print June 1, 2009.
Address for reprints: Michael W. Parra, MD, Division of Trauma Critical Care, Bro-
ward General Medical Center/Level I Trauma Center, 1600 S Andrews Ave, Fort
Lauderdale, FL 33316 (E-mail: michaelwparra@yahoo.com).
J Thorac Cardiovasc Surg 2010;139:e115-6
0022-5223/$36.00
Copyright  2010 Published by Elsevier Inc. on behalf of The American Association
for Thoracic Surgery
doi:10.1016/j.jtcvs.2009.02.052
The Journal of Thoracic and Carworkup to prepare for and avoid potential complications.
This was accomplished in our patient through close collab-
oration of hematology, the blood bank, and the cardiopulmo-
nary bypass team.
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a review of current evidence. Platelets. 2008;19:479-88.Surviving a transfixing cardiac injury caused by a stingray barbMichaelW. Parra, MD,a Eugene N. Costantini, MD, FACS,b Edgar B. Rodas, MD,a Pedro J. Gonzalez, MD,a
Omar J. Salamen, DDS,c Joseph D. Catino, MD,a Paul M. Taber, RN, BSN,a and Ivan Puente, MD, FACS,a
Fort Lauderdale, FlaStingray injuries have a traumatic component (puncture)
and a toxic component (envenomation). Envenomation is
generally not lethal but causes intense pain and significant lo-
cal tissue necrosis. Rare puncture injuries to the thorax or ab-
domen can cause serious injuries and death.1 The following is
a description of what we believe to be the first reported sur-
vivor of a transfixing cardiac injury caused by a stingray barb.
CLINICAL SUMMARY
An 81-year-old man was driving his boat when a spotted
eagle stingray leaped out of the water, struck his torso, and
landed on his lap. The patient was inadvertently stungwith the barb in his left chest and was immediately trans-
ported to a nearby level II trauma center by emergency med-
ical personnel. Physical examination revealed a 2-mm
irregular laceration to the anterior left chest wall just medial
and slightly inferior to the corresponding nipple. A com-
puted tomographic scan of the chest showed a 5% left pneu-
mothorax and a 2-cm linear foreign body penetrating the
anterior chest wall. A left anterior thoracotomy and a pericar-
diotomy were performed in the operating room. After recog-
nizing that the foreign body was intracardiac, the 2
ventricular wall defects were closed with pericardial pled-
gets for hemorrhage control, and the patient was transferred
to our institution. An echocardiogram showed the barb sit-
ting across both the left and right ventricles (Figure 1).
The patient was returned to the operating room, and through
a median sternotomy, he was started on cardiopulmonary
bypass. The right atrium was accessed, and the stingray barb
wasvisualizedbymeans ofgentle tractionof the posterior leaf-
let of the tricuspid valve (Figure 2). The barb was removed in
an antegrade fashion, pulling it through the free wall of the
right ventricle to prevent the barb from causing any additional
trauma. The ventricular septum and the right ventricular free
wall defects were closed with pledgeted Prolene suturesdiovascular Surgery c Volume 139, Number 5 e115
